Strategic Positioning and Market Dynamics

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

• Management identifies a compelling 'vintage' for new originations in the lower middle market as traditional banks and larger private credit funds retreat or move up-market.

• The company is intentionally shifting its focus toward recession-resistant sectors like healthcare and insurance, moving away from the cyclicality and regulatory volatility of the cannabis industry.

• Performance attribution for the quarter was driven by modest increases in interest income, though total investment income declined due to the non-recurrence of a large $1.5 million exit fee from the prior period.

• Management emphasizes a disciplined underwriting approach that prioritizes senior secured first-lien positions with comprehensive maintenance covenants, contrasting this with 'covenant-light' trends in the upper middle market.

• The legacy cannabis portfolio remains the primary source of non-accruals, with management actively pursuing a liquidation strategy through receiverships and asset sales to recover capital.

• Strategic capital allocation included a $2.8 million share repurchase program, which management noted was $0.17 accretive to net asset value per share.

Outlook and Deployment Strategy

• Management expects origination activity to remain 'lumpy and episodic' despite a robust $1.3 billion pipeline, as they prioritize deal quality over deployment speed.

• The company intends to leverage its SEC co-investment relief order to participate in larger transactions alongside affiliates, providing flexibility beyond its own balance sheet constraints.

• Liquidation of legacy assets, specifically the Devi and DMA positions, is expected to conclude within the 2026 calendar year, providing further capital for redeployment.

• Management is targeting an intermediate net debt-to-equity ratio of approximately 1.0x, indicating significant room for leverage expansion from the current 0.53x level.

• Future deployments will focus on cash-flowing borrowers with EBITDA between $5 million and $50 million, primarily within sponsored transactions.

Risk Factors and Portfolio Transitions

• The Justice Grown loan is in maturity default as of May 1, 2026; management has commenced Article 9 foreclosures and engaged advisors to market the underlying assets.

• Management expressed continued caution regarding the cannabis sector, citing a critical lack of available equity capital which hinders the 'refi-ability' of borrowers despite federal rescheduling progress.

• A $1.1 million decline in total investment income quarter-over-quarter was attributed to the absence of one-time fees, highlighting the impact of episodic income on headline metrics.

• The Devi liquidation involves a binding term sheet for $12.5 million in cash proceeds, with a $2 million non-refundable deposit already secured subsequent to quarter-end.